Reproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC HPV prevalence surveys

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 11, 2006, Pages 2148-2153

  Vaccarella, Salvatore ^a   Herrero, Rolando ^b   Dai, Min ^a   Snijders, Peter J F ^c   Meijer, Chris J L M ^c   Thomas, Jaiye O ^d   Anh, Pham Thi Hoang ^e,p   Ferreccio, Catterina ^f   Matos, Elena ^g   Posso, Hector ^h   De Sanjosé, Silvia ⁱ   Shin, Hai Rim ^j   Sukvirach, Sukhon ^k   Lazcano Ponce, Eduardo ^l   Ronco, Guglielmo ^m   Rajkumar, Raj ⁿ   Qiao, You Lin ^o   Muñoz, Nubia ^h   Franceschi, Silvia ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF IBADAN   (Nigeria)

^e National Cancer Institute   (Viet Nam)

^f PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^g UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^h Instituto Nacional de Cancerología   (Colombia)

ⁱ HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^j National Cancer Center   (South Korea)

^k NATIONAL CANCER INSTITUTE   (Thailand)

^l INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^m MOLINETTE HOSPITAL   (Italy)

ⁿ Christian Fellowship Community Health Centre   (India)

^o PEKING UNION MEDICAL COLLEGE   (China)

^p PATH Canada   (Viet Nam)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH SURVEY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; ORAL CONTRACEPTION; PARITY; POLYMERASE CHAIN REACTION; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; REPRODUCTIVE HEALTH; RISK ASSESSMENT; VIRUS INFECTION; WART VIRUS;

ADOLESCENT; ADULT; AGE FACTORS; ALPHAPAPILLOMAVIRUS; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PARITY; POLYMERASE CHAIN REACTION; PREGNANCY; PREVALENCE; UTERINE CERVICAL NEOPLASMS;

EID: 33845289450     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0556     Document Type: Article

References (52)

1. IARC. Monographs on the evaluation of carcinogenic risks to humans. Human papillomavirus. Volume 64. International Agency for Research on Cancer: Lyon; 1995.
2. Vaccarella S, Franceschi S, Herrero R, et al. Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol Biomarkers Prev 2006;15:326-33.
3. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
4. Castellsague X, Muñoz N. Chapter 3: Cofactors in human papillomavirus cardnogenesis - role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003;31:20-8.
5. Hildesheim A, Herrero R, Castle PE, et al. HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer 2001;84:1219-26.
6. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer 2006;119:1108-24.
7. Smith JS, Green J, Berrington de González A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003;361:1159-67.
8. Ylitalo N, Sorensen P, Josefsson A, et al. Smoking and oral contraceptives as risk factors for cervical carcinoma in situ. Int J Cancer 1999;81:357-65.
9. Muñoz N, Franceschi S, Bosetti C, et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002;359:1093-101.
10. Deacon JM, Evans CD, Yule R, et al. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer 2000;83:1565-72.
11. Moreno V, Bosch FX, Muñoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002;359:1085-92.
12. Herrero R, Castle PE, Schiffman M, et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005;191:1796-807.
13. Muñoz N, Mendez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004;190:2077-87.
14. Giuliano AR, Papenfuss M, Abrahamsen M, Inserra P. Differences in factors associated with oncogenic and nononcogenic human papillomavirus infection at the United States-Mexico border. Cancer Epidemiol Biomarkers Prev 2002;11:930-4.
15. Giuliano AR, Papenfuss M, Abrahamsen M, et al. Human papillomavirus infection at the United States-Mexico border: implications for cervical cancer prevention and control. Cancer Epidemiol Biomarkers Prev 2001;10:1129-36.
16. Giuliano AR, Papenfuss M, Schneider A, Nour M, Hatch K. Risk factors for high-risk type human papillomavirus infection among Mexican-American women. Cancer Epidemiol Biomarkers Prev 1999;8:615-20.
17. Peyton CL, Gravitt PE, Hunt WC, et al. Determinants of genital human papillomavirus detection in a US population. J Infect Dis 2001;183:1554-64.
18. Green J, Berrington de González A, Smith JS, et al. Human papillomavirus infection and use of oral contraceptives. Br J Cancer 2003;88:1713-20.
19. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218-26.
20. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001;285:2995-3002.
21. Burk RD, Kelly P, Feldman J, et al. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Transm Dis 1996;23:333-41.
22. Bauer HM, Hildesheim A, Schiffman MH, et al. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. Sex Transm Dis 1993;20:274-8.
23. ter Meulen J, Eberhardt HC, Luande J, et al. Human papillomavirus (HPV) infection, HIV infection and cervical cancer in Tanzania, East Africa. Int J Cancer 1992;51:515-21.
24. Collins SI, Mazloomzadeh S, Winter H, et al. Proximity of first intercourse to menarche and the risk of human papillomavirus infection: a longitudinal study. Int J Cancer 2005;114:498-500.
25. Smith EM, Johnson SR, Ritchie JM, et al. Persistent HPV infection in postmenopausal age women. Int J Gynaecol Obstet 2004;87:131-7.
26. Pham TH, Nguyen TH, Herrero R, et al. Human papillomavirus infection among women in South and North Vietnam. Int J Cancer 2003;104:213-20.
27. Sukvirach S, Smith JS, Tunsakul S, et al. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis 2003;187:1246-56.
28. Shin HR, Lee DH, Herrero R, et al. Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer 2003;103:413-21.
29. Franceschi S, Rajkumar R, Snijders PJF, et al. Papillomavirus infection in rural women in southern India. Br J Cancer 2005;92:601-6.
30. Dai M, Bao YP, Li N, et al. Human papillomavirus infection in Shanxi Province, People's Republic of China: a population-based study. Br J Cancer 2006;95:96-101.
31. de Sanjosé S, Almirall R, Lloveras B, et al. Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis 2003;30:788-93.
32. Ronco G, Ghisetti V, Segnan N, et al. Prevalence of human papillomavirus infection in women in Turin, Italy. Eur J Cancer 2005;41:297-305.
33. Lazcano-Ponce E, Herrero R, Munoz N, et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 2001;91:412-20.
34. Matos E, Loria D, Amestoy GM, et al. Prevalence of human papillomavirus infection among women in Concordia, Argentina: a population-based study. Sex Transm Dis 2003;30:593-9.
35. Ferreccio C, Prado RB, Luzoro AV, et al. Population-based prevalence and age distribution of human papillomavirus among women in Santiago, Chile. Cancer Epidemiol Biomarkers Prev 2004;13:2271-6.
36. Molano M, Posso H, Weiderpass E, et al. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer 2002;87:324-33.
37. Thomas JO, Herrero R, Omigbodun AA, et al. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. Br J Cancer 2004;90:638-45.
38. Wright TC, Jr., Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287:2120-9.
39. Jacobs MV, Roda Husman AM, van den Brule AJ, Snijders PJF, Meijer CJLM, Walboomers JM. Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol 1995;33:901-5.
40. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJLM, Snijders PJF. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002;40:779-87.
41. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol 1998;36:3020-7.
42. Jacobs MV, Snijders PJF, Voorhorst FJ, et al. Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison. J Clin Pathol 1999;52:498-503.
43. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
44. Easton DF, Peto J, Babiker AG. Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med 1991;10:1025-35.
45. Plummer M. Improved estimates of floating absolute risk. Stat Med 2004;23:93-104.
46. Sellors JW, Karwalajtys TL, Kaczorowski J, et al. Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ 2003;168:421-5.
47. Richardson H, Abrahamowicz M, Tellier PP, et al. Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students. Cancer Epidemiol Biomarkers Prev 2005;14:1149-56.
48. Flores R, Papenfuss M, Klimecki WT, Giuliano AR. Cross-sectional analysis of oncogenic HPV viral load and cervical intraepithelial neoplasia. Int J Cancer 2006;118:1187-93.
49. IARC. Monographs on the evaluation of carcinogenic risks to humans: hormonal contraception and post-menopausal hormonal therapy. Volume 72: 1999. IARC.
50. Brake T, Lambert PF. Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci U S A 2005;102:2490-5.
51. Arbeit JM, Howley PM, Hanahan D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci U S A 1996;93:2930-5.
52. Mitrani-Rosenbaum S, Tsvieli R, Tur-Kaspa R. Oestrogen stimulates differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells. J Gen Virol 1989;70:2227-32.